Supplemental Figure S1

Supplemental Figure S1

RFS probability according to tumour staging (A) and tumour localization (B).

A multivariate Cox analysis including tumour staging and tumour localization gave p values at 0.003 and 0.093, for tumour staging and tumour localization, respectively.

A: RR was 5.71 (95% CI, 0.77-42.4) for stage II (green line, 111 patients, 21 events) and 12.60 (95% CI, 1.73-91.8) for stage III (blue line, 101 patients, 38 events), as compared to stage I (brown line, 27 patients, one event, Cox: p = 0.001): Log rank p<0.001.

B: RR was 0.67 (95% CI, 0.38-1.18) for left/sigmoid/recto-sigmoid junction (green line, 118 patients, 23 events) and 1.63 (95% CI, 0.83-3.20) for rectum (brown line, 31 patients, 13 events), as compared to right/transverse colon (blue line, 89 patients, 24 events, Cox: p = 0.035): Log rank p = 0.029.

Supplemental Figure S2

RFS probability in stage II patients according to MMR status (A) and KRAS status (B). Overall Log rank test adjusted for tumour staging (stage II-III), p = 0.18.

A: Stage II patients with pMMR (blue line, 90 patients, 17 events) or dMMR tumour (green line, 17 patients, 4 events): Log rank, p = 0.58. Overall Log rank test performed on stage II-III patients, adjusted for tumour staging gave p = 0.18.

B: Stage II patients with KRAS wt tumour (green line, 75 patients, 17 events) or KRAS-mutated tumour (black line, 36 patients, 4 events): Log rank, p = 0.12. Overall Log rank test performed on stage II-III patients, adjusted for tumour staging gave p = 0.21.

Supplemental Figure S1

Supplemental Figure S2